Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial

伯氨喹 青蒿琥酯 医学 甲氟喹 蒿甲醚 阿莫地喹 哌喹 羽扇豆碱 蒿甲醚/麝香草醚 疟疾 青蒿素 固定剂量组合 双氢青蒿素 内科学 恶性疟原虫 药理学 氯喹 免疫学
作者
Frank Smithuis,Moe Kyaw Kyaw,Ohn Phe,Thein Win,Pyay Phyo Aung,Aung Pyay Phyo Oo,Arkar Linn Naing,Mya Yee Nyo,Naing Zaw Htun Myint,Mallika Imwong,Elizabeth A. Ashley,Sue J. Lee,Nicholas J. White
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:10 (10): 673-681 被引量:173
标识
DOI:10.1016/s1473-3099(10)70187-0
摘要

BackgroundArtemisinin-combination therapy (ACT) is recommended as first-line treatment of falciparum malaria throughout the world, and fixed-dose combinations are preferred by WHO; whether a single gametocytocidal dose of primaquine should be added is unknown. We aimed to compare effectiveness of four fixed-dose ACTs and a loose tablet combination of artesunate and mefloquine, and assess the addition of a single gametocytocidal dose of primaquine.MethodsIn an open-label randomised trial in clinics in Rakhine state, Kachin state, and Shan state in Myanmar (Burma) between Dec 30, 2008, and March 20, 2009, we compared the effectiveness of all four WHO-recommended fixed-dose ACTs (artesunate–mefloquine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, artemether–lumefantrine) and loose artesunate–mefloquine in Burmese adults and children. Eligible patients were those who presented to the clinics with acute uncomplicated Plasmodium falciparum malaria or mixed infection, who were older than 6 months, and who weighed more than 5 kg. Treatments were randomised in equal numbers within blocks of 50 and allocation was in sealed envelopes. All patients were also randomly assigned to receive either a single dose of primaquine 0·75 mg base/kg or not. Patients were followed up for 63 days. Treatment groups were compared by analysis of variance and multiple logistic regression. The primary outcome was the 63 day recrudescence rate. This study is registered with clinicaltrials.gov, number NCT00902811.Findings155 patients received artesunate–amodiaquine, 162 artemether–lumefantrine, 169 artesunate–mefloquine, 161 loose artesunate–mefloquine, and 161 dihydroartemisinin–piperaquine. By day 63 of follow-up, 14 patients (9·4%; 95% CI 5·7–15·3%) on artesunate–amodiaquine had recrudescent P falciparum infections, a rate significantly higher than for artemether–lumefantrine (two patients; 1·4%; 0·3–5·3; p=0·0013), fixed-dose artesunate–mefloquine (0 patients; 0–2·3; p<0·0001), loose artesunate–mefloquine (two patients; 1·3%; 0·3–5·3; p=0·0018), and dihydroartemisinin–piperaquine (two patients 1·3%; 0·3–5·2%; p=0·0012). Hazard ratios for re-infection (95% CI) after artesunate–amodiaquine were 3·2 (1·3–8·0) compared with the two artesunate–mefloquine groups (p=0·01), 2·6 (1·0–6–0) compared with artemether–lumefantrine (p=0·04), and 2·3 (0·9–6·0) compared with dihydroartemisinin–piperaquine (p=0·08). Mixed falciparum and vivax infections were common: 129 (16%) had a mixed infection at presentation and 330 (41%) patients had one or more episodes of Plasmodium vivax infection during follow-up. The addition of a single dose of primaquine (0·75 mg/kg) reduced P falciparum gametocyte carriage substantially: rate ratio 11·9 (95% CI 7·4–20·5). All regimens were well tolerated. Adverse events were reported by 599 patients, most commonly vomiting and dizziness. Other side-effects were less common and were not related to a specific treatment.InterpretationArtesunate–amodiaquine should not be used in Myanmar, because the other ACTs are substantially more effective. Artesunate–mefloquine provided the greatest post-treatment suppression of malaria. Adding a single dose of primaquine would substantially reduce transmission potential. Vivax malaria, not recurrent falciparum malaria, is the main complication after treatment of P falciparum infections in this region.FundingMédecins sans Frontières (Holland) and the Wellcome Trust Mahidol University Oxford Tropical Medicine Research Programme.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
555557应助年轻的烨华采纳,获得10
刚刚
3秒前
hjjjjj1发布了新的文献求助10
3秒前
5秒前
冬瓜熊发布了新的文献求助10
5秒前
白桥发布了新的文献求助10
6秒前
7秒前
sjie完成签到 ,获得积分10
8秒前
平淡的凝竹完成签到,获得积分10
9秒前
林正心发布了新的文献求助20
9秒前
hjjjjj1完成签到,获得积分10
10秒前
付其喜完成签到,获得积分10
10秒前
阿航发布了新的文献求助30
10秒前
Gloria完成签到,获得积分10
12秒前
pluto应助believe采纳,获得10
12秒前
12秒前
12秒前
12秒前
臧佳莹发布了新的文献求助10
13秒前
小胡完成签到,获得积分10
13秒前
风中亦旋完成签到,获得积分10
15秒前
赘婿应助Pom采纳,获得10
17秒前
CaoRouLi发布了新的文献求助10
17秒前
阿航完成签到,获得积分20
17秒前
橘子发布了新的文献求助10
18秒前
18秒前
www发布了新的文献求助10
19秒前
NexusExplorer应助小豆芽采纳,获得10
19秒前
11发布了新的文献求助10
20秒前
22秒前
liangye2222发布了新的文献求助10
23秒前
23秒前
白桥完成签到,获得积分10
23秒前
23秒前
科研通AI2S应助科研通管家采纳,获得10
25秒前
25秒前
czh应助科研通管家采纳,获得10
25秒前
Orange应助科研通管家采纳,获得10
25秒前
橘子完成签到,获得积分10
25秒前
隐形曼青应助科研通管家采纳,获得10
25秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988975
求助须知:如何正确求助?哪些是违规求助? 3531316
关于积分的说明 11253424
捐赠科研通 3269917
什么是DOI,文献DOI怎么找? 1804830
邀请新用户注册赠送积分活动 882063
科研通“疑难数据库(出版商)”最低求助积分说明 809068